13.94
+0.08(+0.58%)
Currency In USD
| Previous Close | 13.86 |
| Open | 14.08 |
| Day High | 14.46 |
| Day Low | 13.93 |
| 52-Week High | 19.18 |
| 52-Week Low | 3.73 |
| Volume | 1.15M |
| Average Volume | 1.81M |
| Market Cap | 763.19M |
| PE | -3.18 |
| EPS | -4.38 |
| Moving Average 50 Days | 14.45 |
| Moving Average 200 Days | 11.51 |
| Change | 0.08 |
If you invested $1000 in uniQure N.V. (QURE) 10 years ago, it would be worth $531.25 as of July 01, 2025 at a share price of $13.94. Whereas If you bought $1000 worth of uniQure N.V. (QURE) shares 5 years ago, it would be worth $301.67 as of July 01, 2025 at a share price of $13.94.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
GlobeNewswire Inc.
Jun 11, 2025 12:00 PM GMT
~ Proven biotech executive to lead commercialization of AMT-130 in Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapi
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
GlobeNewswire Inc.
Jun 02, 2025 11:05 AM GMT
~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, June 02, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (
uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)
GlobeNewswire Inc.
May 29, 2025 11:05 AM GMT
~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to be presented today at Epilepsy Therapies & Diagnostics Development Symposium (ETDD) ~ LEXING